Medigen Biotechnology Corp. announced the appointment of Mr. Chieh-Liang Lin, Senior Associate Vice President of Cell Therapy Department of the company, as Chief Scientific Officer. Approved by the Board of Directors on March 11, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.75 TWD | +1.83% | +5.70% | -6.81% |
1st Jan change | Capi. | |
---|---|---|
-6.81% | 177M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- 3176 Stock
- News Medigen Biotechnology Corp.
- Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer